Drugs / PIPE-307
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04941781 | Sep → Nov 2021 | multiple sclerosis | Contineum Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04725175 | Feb → Sep 2021 | multiple sclerosis | Contineum Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06083753 | Nov 2023 → Jul 2025 | relapsing-remitting multiple sclerosis | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIPE-307 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04725175 ↗ |
| Route | Oral | “Single and multiple ascending oral doses of PIPE-307 tablets” NCT04725175 ↗ |